Gauss

Recombinant Mouse CCL5 (RANTES) (carrier-free) 25 µg

Réf. UGAP : 3689595 Réf. Fournisseur : 594204 Réf. Constructeur : 594204
Recombinant Mouse CCL5 (RANTES) (carrier-free) 25 µg
Recombinant Mouse CCL5 (RANTES) (carrier-free) 25 µg
Franco de port et d'emballage pour toutes les commandes supérieures à 80€ HT.

Produit ni repris ni échangé excepté en cas d’erreur du prestataire.
La quantité choisie doit être comprise entre 1 et 999 999.

Points clés

CCL5 is a CC chemokine that directs the migration of leukocytes in immune and inflammatory responses. Increased CCL5 expression has been associated with a wide range of inflammatory disorders and pathologies. It has been shown that CCL5 is highly expressed by breast tumor cells at primary tumor sites and is strongly associated with the progression of breast cancer. CCL5 may contribute to tumor progression by recruiting monocytes into tumor sites, and CCL5 can also stimulate the release of MMP, thereby promoting tumor cell migration. Some studies also show that CCL5 has pro-angiogenesis effects in vivo and in vitro. CCL5 oligomerization and binding to GAGs can induce angiogenic effects through its receptor CCR1 and CCR5. CCL5 is expressed in the early stages of many viral infections. It has been shown that CCL5 is protective against many viruses including influenza, RSV, HCMV, HCV, and HIV. CCL5 can inhibit HIV infection by competing with the virus for CCR5 binding. CCL5 also has been implicated in the development of asthma, artherosclerosis, and fibrosis.;

En savoir plus

Garantie

Garantie 0 Mois

Description

CCL5 is a CC chemokine that directs the migration of leukocytes in immune and inflammatory responses. Increased CCL5 expression has been associated with a wide range of inflammatory disorders and pathologies. It has been shown that CCL5 is highly expressed by breast tumor cells at primary tumor sites and is strongly associated with the progression of breast cancer. CCL5 may contribute to tumor progression by recruiting monocytes into tumor sites, and CCL5 can also stimulate the release of MMP, thereby promoting tumor cell migration. Some studies also show that CCL5 has pro-angiogenesis effects in vivo and in vitro. CCL5 oligomerization and binding to GAGs can induce angiogenic effects through its receptor CCR1 and CCR5. CCL5 is expressed in the early stages of many viral infections. It has been shown that CCL5 is protective against many viruses including influenza, RSV, HCMV, HCV, and HIV. CCL5 can inhibit HIV infection by competing with the virus for CCR5 binding. CCL5 also has been implicated in the development of asthma, artherosclerosis, and fibrosis.;

Caractéristiques

Fournisseur
BioLegend Europe BV
Marque
BIOLEGEND
Référence fabricant
594204
Référence distributeur
594204
Vendu par
25 μg
Quantité
N/A
Lieu de fabrication
USA
Lieu de stockage
Pays-Bas ou USA
Référence fabriquant similaire
594202
Soumis à carboglace
non
Classement dans le catalogue fournisseur
Recombinant Protein
Certification
RUO
Type d’application
culture cellulaire
Type de produit
protéine
Température de conservation (°C)
-20 ou -70 °C
Température de transport
Blue Ice
Organisme cible
Mouse
Source biologique
E. coli
Seuil de coupure des masses moléculaires MWCO
The 68 amino acid recombinant protein has a predicted molecular mass of approximately 7.8 kD. The DTT-reduced protein migrates at approximately 10 kD and non-reduced protein migrates at approximately 11 kD by SDS-PAGE. Da
Concentration
10 and 25 µg sizes are bottled at 200 µg/mL. 100 µg size and larger sizes are lot-specific and bottled at the concentration indicated on the vial. To obtain lot-specific concentration, please enter the lot number in our online tools.
Pureté
>97%, as determined by Coomassie stained SDS-PAGE. %
Matière dangereuse
Non
Code douanier
38220000
Classement NCBI
20304
Nomenclature Nacres
NA.77
Nomenclature IFPEN
NA.77
Nomenclature CEA
SGP01
Nomenclature IRSN
273
Nomenclature INSERM
NA.NA77
Nomenclature CNRS
NA77
Nomenclature CHU
18.551
Nomenclature DGOS
LD11AOOO
Type d'échantillon
culture cellulaire
Reprise en cas d’erreur client
non